Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/01—Hydrocarbons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/31—Hydrocarbons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/345—Alcohols containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin

Definitions

• the invention relates to the field of treatment of pathologies and conditions associated with an impaired skin barrier function.
• the epidermis is a pluristratified epithelium, of ectodermal origin, in perpetual renewal.
• keratinocytes are composed of several cell types: more than 90% keratinocytes but also Langerhans cells, Merkel cells and melanocytes.
• the basal layer There are several layers of different morphological and cellular composition, from the inside to the outside: the basal layer, a cell layer whose keratinocytes have a very strong proliferation capacity which makes it possible to ensure the self-renewal of the cell. epidermis, then the suprabasal layers (granular, thorny layers) and finally the stratum corneum (Stratum Corneum, SC).
• One of the fundamental functions of the skin is to ensure a barrier between the body and the external environment, opposing in one way the penetration into the epidermis of fungi, bacteria and allergens of the environment and in the other direction to loss of water.
• the quality of the barrier function is evaluated in vivo in humans by measuring the insensible loss of water and the rate of hydration and in the mouse by death by dehydration of embryos, dermal permeability to a dye or decrease body weight.
• the integrity of the extracellular lipid cement as well as all the cellular elements of the stratum corneum and the balance between keratinocyte proliferation and differentiation are essential for maintaining a functional epidermal barrier function.
• the pH gradient regulates the activities of the different enzymes and thus contributes to the balance of the barrier.
• the concentration of calcium ions influences the composition of the extracellular cement of the stratum corneum and thus the equilibrium of the epidermal barrier (Lee et al., Calcium and potassium are important regulators of barrier homeostasis in murine epidermis,
• One of the functions of water in the stratum corneum is to allow the enzymatic hydrolysis reactions necessary for the flexibility of the skin and for normal desquamation. If the amount of water present in the SC falls below a critical threshold, enzymatic reactions are disrupted, leading to the adhesion of corneocytes and the accumulation of cells on the surface of the skin.
• Cutaneous hydration is based on two phenomena: the supply of water through the trans-epidermal flow brought from the bloodstream and the retention of epidermal water which involves the cutaneous barrier function.
• the barrier to water losses is not absolute.
• the normal movement of water between the outer and inner environment through the stratum corneum is called TEWL (transepidermal water loss) and is a part of the water insensitive loss.
• the cutaneous barrier function is impaired in most of the skin diseases most common in the population and often accompanied by an inflammatory component (psoriasis, atopic dermatitis, ichthyosis, dry skin ). It is also so in a large number of physiological states in response to weather (skin aging) or environmental aggressions
• the disruption of the barrier function makes the body more sensitive to external aggression and dehydration. It may be associated with dysregulation of desquamation and hyperproliferation (Jackson et al., Pathobiology of stratum corneum, West J. Med, 158, 279-285, 1993).
• the application FR2847467 relates to the use of at least one agent that modulates the activity of the oxysterol 7 ⁇ -hydroxylase for the preparation of a cosmetic composition intended for preventing and / or treating cutaneous disorders and / or membranes of the type mucous membranes affecting the proper functioning of the skin barrier.
• Application FR2831443 relates to the use of at least one extract of
• Gingko biloba or Olea europaea for the preparation of a composition intended to improve the barrier function of the skin.
• the application FR2905857 relates to the use of a composition comprising a carob pulp extract to moisturize and / or protect from dry skin.
• the inventors have demonstrated that this combination restores a protective and functional skin barrier. They evaluated the moisturizing activity of this combination and subsequent enhancement of skin barrier function using an in vivo skin model of induced skin dehydration. In addition, they observed the expression of molecular epidermal markers potentially involved in the homeostasis of the epidermal barrier function by quantitative PCR and immunohistochemistry. The inventors also monitored serine protease activity by in situ zymography and skin barrier functionality using fluorescent probes. The results show that the combination of glycerol, petrolatum and liquid paraffin in the form of an oil-in-water or water-in-oil emulsion makes it possible to restore the serine protease activity and to suppress the inflammation induced by the stress.
• Vaseline as an occlusive and emollient agent is particularly important in the composition. Indeed, by forming a protective film on the skin, it helps to compensate for the impairment of the impaired barrier function. The quality of the film formed on the skin depends very strongly on the rheological properties of the petroleum jelly used in the manufacture.
• composition for topical use comprising, as active ingredient, a combination of glycerol, petrolatum and liquid paraffin, in the form of an oil-in-water or water-in-oil emulsion.
• active combination means the combination of glycerol, petrolatum and liquid paraffin, in the form of an oil-in-water or water-in-oil emulsion.
• glycerol, petrolatum and liquid paraffin have the criteria described and controlled according to "European Pharmacopeia", 6th Edition.
• the vaseline of the active combination has a dropping point of between 35 and 70 ° C., preferably of between 51 and 57 ° C., particularly preferably of about 54 ° C.
• the drop point is measured according to the method 2.2.17 described in "European Pharmacopeia", 6th Edition.
• the vaseline of the active combination has a consistency of between 175 and 195 1/10 mm, preferably about 185 1/10 mm (cone penetration at 25 ° C).
• the vaseline of the active combination has a viscosity of between 4 and 5 cSt at 100 ° C., preferably about 4.8 cSt at 100 ° C.
• the vaseline of the active combination has a spectrum in 500 MHz NMR spectroscopy of C13 carbon comprising a peak at 24.55 ppm, the area relative to a control of Tetra methyl sylan (TMS) at 1% is between 4 and 8.
• the active combination is present in a proportion of between 10 and 50% and preferably between 20 and 30% by weight relative to the total weight of the composition; the concentration of glycerol is between 5 and 30%, preferably between 10 and 20% and particularly preferably is about 15% by weight relative to the total weight of the composition, the petrolatum concentration is between 3 and 20%. %, preferably between 5 and 10% and particularly preferably is about 8% by weight relative to the total weight of the composition and the liquid paraffin concentration is between 0.5 and 5%, preferably between 1 and 3 % and particularly preferably is about 2% by weight relative to the total weight of the composition.
• the water is between 30 and 80% by weight relative to the total weight of the composition.
• the composition according to the invention comprises approximately 15% of glycerol, approximately 8% of petrolatum and approximately 2% of liquid paraffin by weight relative to the total weight of the composition.
• the dermatological composition according to the invention further comprises conventional dermatologically compatible excipients.
• the dermatological composition according to the present invention may be prepared in the form of a water-in-oil (W / O) or oil-in-water (O / W) emulsion, a multiple emulsion such as, for example, a water-in-oil emulsion.
• W / O / W water-in-oil
• O / W oil-in-water
• W / O / H oil-in-water emulsion
• a hydrodispersion or a lipodispersion a gel or an aerosol.
• the dermatologically compatible excipients may be any excipient among those known to those skilled in the art to obtain a composition for topical application in the form of a cream, a lotion, a gel or an ointment. , an emulsion, a microemulsion, a spray, etc.
• the composition according to the invention can in particular contain additives and formulation aids, such as emulsifiers, thickeners, gelling agents, water binders, spreading agents, stabilizers, dyes, perfumes and the like. conservatives.
• Suitable emulsifiers include stearic acid, trolamine, PEG-40-stearate.
• the composition according to the invention has about 5% emulsifiers by weight relative to the total weight of the composition.
• the composition according to the invention has between 1 and 5% of stearic acid, preferably about 3% by weight relative to the total weight of the composition.
• the composition according to the invention has between 0 and 2% of trolamine, preferably about 0.5% by weight relative to the total weight of the composition.
• the composition according to the invention has between 0 and 2% of PEG-40-stearate, preferably about 0.5% by weight relative to the total weight of the composition.
• Suitable thickeners include glycerol monostearate, PEG 600.
• the composition according to the invention has about 5% thickeners by weight relative to the total weight of the composition.
• the composition according to the invention has between 2 and 10% of glycerol monostearate, preferably about 5% by weight relative to the total weight of the composition.
• the composition according to the invention has between 2 and 10% of PEG 600, preferably about 5% by weight relative to the total weight of the composition.
• Suitable preservatives include propyl parahydroxybenzoate, chlorocresol.
• the composition according to the invention has about 0.1% preservatives by weight relative to the total weight of the composition.
• the composition according to the invention has between 0.05 and 1% of propyl parahydroxybenzoate, preferably about 0.1% by weight relative to the total weight of the composition.
• Suitable leveling agents include dimethicone, polydimethylcyclosiloxane.
• the composition according to the invention has about 2% spreading agents by weight relative to the total weight of the composition.
• the composition according to the invention has between 0.2 and 2% dimethicone, preferably about 0.5% by weight relative to the total weight of the composition.
• the composition according to the invention has between 1 and 3% of polydimethylcyclosiloxane, preferably about 2.5% by weight relative to the total weight of the composition.
• Suitable water fixatives include polyethylene glycol, preferably polyethylene glycol 600.
• the composition according to the invention has about 8% water fixers by weight relative to the total weight of the composition.
• the composition according to the invention has between 2 and 10% of polyethylene glycol, preferably about 5% by weight relative to the total weight of the composition.
• the water used for the aqueous phase of the emulsion may be distilled water or thermal water having dermato-cosmetic properties.
• the composition according to the invention comprises: approximately 15% of glycerol, approximately 8% of petrolatum, approximately 2% of liquid paraffin, and as excipients: approximately 1 to 5% of stearic acid,
• the present invention also relates to the use of a composition according to the invention for the preparation of a medicament for treating dry skin conditions, in particular certain dermatoses such as atopic dermatitis, ichthyotic conditions, psoriasis.
• the present invention also relates to the use of a composition according to the invention for the preparation of a medicament for treating superficial burns of small areas.
• the present invention also relates to the use of a composition according to the invention for the preparation of a medicament for preventing and / or treating / reducing the frequency and intensity of eczematous flares observed in patients with dermatitis atopic.
• Figure 1 NMR spectrum at 500 MHz C13 carbon of 5 g sample Syntadex A Vaseline (Syntheal) and Composition A.
• composition A Composition A
• composition A '
• PEG-40-stearate 0.5 g of PEG-40-stearate, and as excipients stearic acid, glycerol monostearate, polydimethylcyclosiloxane, dimethicone, polyethylene glycol 600, chlorocresol,
• composition A we evaluate the moisturizing activity of composition A and the subsequent improvement of skin barrier function using a skin model ex vzvo of induced skin dehydration.
• the laboratory retrieves skin samples from plastic surgery surgical waste (breast reduction).
• the use of these samples comes within the framework of "the declaration of activity of conservation and preparation of elements of the human body for the research program needs of the Pierre Fabre group" made to the Ministry of Higher Education and the research.
• RNA expression After treatment, 2 biopsies of 6 mm diameter were taken for analysis of RNA expression and a 4 mm diameter biopsy included in a Tissue Tek® (Sakura Finetek) resin block for histology.
• Tissue Tek® Sekura Finetek
• protein analysis the skin is exposed to heat shock in a water bath at 60 ° C. for 5 minutes and then at 4 ° C. for 2 minutes in order to separate the epidermis from the dermis.
• Biopsies and epidemics are frozen in liquid nitrogen and stored at -80 ° C. before being analyzed.
• RNA 6000 Nano LabChip® chips The skin biopsies are ground in a mortar previously cooled with liquid nitrogen and the RNAs are extracted using an RNeasy® kit (QIAGEN) according to the supplier's recommendations. The RNA is then assayed using a Bio analysesr 2100® (Agilent Technologies) on RNA 6000 Nano LabChip® chips. The cDNA is obtained from 1 ⁇ g of RNA by retro-transcription enzymatic reaction carried out with an Access RT-PCR Core Reagents® kit (Promega), using oligo dT primers. The levels of gene expression are analyzed by quantitative PCR on a thermocycler.
• ICycler iQ® fluorescence (Biorad) with iQ TM SYBR® Green Super Mix PCR kits (Biorad) following a 40-cycle protocol comprising denaturation at 95 ° C (15 sec) and elongation at 60 ° C (1 mm).
• the accumulation of the PCR product proportional to the fluorescence emission (intercalating SYBR®Green) is visualized cycle by cycle thanks to the iCycler software.
• ICycler version 3.1 analysis software delivers raw CT values
• the induction factor (FI) is then calculated for each treatment with respect to the corresponding control condition.
• FI 2 " ⁇ Cr
• control without stress corresponds to the control not desiccated
• stressed corresponds to a skin biopsy that was dried for 2 hours and then spent 2 additional hours in a control condition (ie without topical treatment)
• condition "treated” is the skin which has undergone 2 hours of drying followed by 2 hours of topical treatment with an emollient.
• the treated epidemics are ground in a mortar cooled with liquid nitrogen and the proteins are extracted in a lysis buffer RIPA (Tris HCl pH8 50mM, NaCl 15OmM, Triton X 100 IX, Na + Desoxycholate 1%, SDS 0.1% 5mM EDTA, 10mM DTT, protease inhibitor cocktail (reference P8340, SIGMA).
• RIPA Tris HCl pH8 50mM, NaCl 15OmM, Triton X 100 IX, Na + Desoxycholate 1%, SDS 0.1% 5mM EDTA, 10mM DTT, protease inhibitor cocktail (reference P8340, SIGMA).
• the proteins are then assayed by the DC-DC Protein Assay method.
• the protein mixture is separated by electrophoresis using the Mini system
• Protein II Biorad
• proteins are transferred to a PVDF membrane (Hybond-P, Amersham).
• the protein of interest is revealed by a specific antibody and an ECL + kit (Amersham).
• the amount of protein and the proportion of degraded form are calculated using Image Master TotalLab version 1.11 software (Amersham) after normalization with respect to ⁇ - actin (reference protein).
• Cryocuts are fixed for 10 minutes with acetone at 20 ° C. and then rehydrated with PBS before being analyzed by immunochemical staining. After fixation and rehydration, the skin sections are saturated with a 3% BSA solution and incubated for 1 hour with the primary antibody directed against the protein of interest. In a second time, they are incubated for 1 hour with the secondary antibody coupled to a fluorochrome Alexa-488 or Alexa-555 and finally mounted in Mowiol containing DAPI to mark the nuclei.
• the sections are rinsed in a washing solution (Tween 20 1% in water) and incubated for 2 hours at 37 ° C. with a solution containing the specific substrate.
• enzymes of interest coupled to a fluorophore (annex).
• annex a solution containing the specific substrate.
• enzymes of interest coupled to a fluorophore (annex).
• the fluorophore is cleaved, releasing a fluorescent signal observable under a microscope.
• the labeled slides are then observed using an epifluorescence microscope (Nikon Eclipse 5Oi) or a Zeiss Axiovert 100 inverted confocal microscope.
• the skin explants are incubated for an additional hour in an oven at 37 ° C with a fluorescent probe
• Lucifer Yellow Carboxyhydrazide dilithium is known (Invitrogen) at 1M in HBSS buffer. The skin is then rinsed in an HBSS bath for 1 minute and then 4mm diameter biopsies are taken and included in the resin Tissue TekR® (Sakura Finetek) (Matsuki et al 1998). The skin is then cut, the nuclei are labeled with DAPI and the slides are observed under a fluorescence microscope at a wavelength of 450 nm as described above.
• the first analysis consisted in studying a fundamental functional parameter in the cutaneous barrier function: the permeability of the upper layers of the epidermis. Incubation of the skin with a fluorescent probe (Lucifer Yellow) after the drying experiment allowed to characterize the modulation of cutaneous permeability. In the control condition, the marking is very weak and superficial, the probe penetrates little through the stratum corneum and is eliminated during rinsing. After two hours of drying, the marking is observable in the deeper strata of the stratum corneum. Drying makes the skin more permeable, its barrier function is deteriorated. The topical treatment with the composition After drying for two hours restores the impermeability of the SC with respect to the probe, the marking is again weak and superficial, as in the control condition. We can then conclude that the moisturizing treatment has a repairing effect on the parched skin and the cutaneous barrier function observable on the tissue model.
• the expression of different genes potentially involved in the homeostasis of the epidermal barrier function was measured by quantitative PCR under the various stress conditions or treatment of the drying model. Immunohistochemistry analysis has shown the reorganization of the expression of certain proteins in terms of localization, for example tight junctions. Degradation of corneodesmosomal proteins was analyzed by Western-Blot. The targets studied using these different approaches have been grouped according to their physiological role (see Table 1). The objective of this study is to observe a visualizable stress response and a correction of the effect of stress by the topical application of the composition A.
• Table 1 Summary of Targets and Pharmacological Response Considered in the Desiccation Model.
• the activity of the serine proteases was evaluated by in situ zymography on the dehydration model and observed under a confocal microscope in the control condition after two hours of drying and after two hours of drying followed by a two-hour incubation with the composition A
• the marking is the most intense in the control condition, it corresponds to the normal strong activity. This marking decreases and becomes irregular along the stratum corneum after two hours of drying while its intensity is increased and the location of the activity reorganized after the two hours of incubation with the composition A.
• the drying has the effect of reducing and disrupt enzymatic activity.
• composition A is capable of restoring the enzymatic activity of the dehydrated skin, which confirms the effect of this composition for a return of the homeostasis of the desquamation.
• composition A makes it possible to restore the level of expression of the molecular targets whose expression is increased by the stress of cutaneous dehydration induced.
• Composition A also makes it possible to restore serine protease activity.
• topical application of the composition A makes it possible to eliminate the inflammation induced by the stress.
• composition A in topical application makes it possible to restore the barrier function of the skin, to limit
• Syntadex A (Syntheal) petroleum jelly has a characteristic spectrum in C13 carbon NMR spectroscopy at 500 MHz, including a peak at 24.55 ppm, the area of which is related to a 1% Tetra methyl sylan (TMS) control. between 4 and 8.
• TMS Tetra methyl sylan

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Birds (AREA)
• Emergency Medicine (AREA)
• Toxicology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Developing Agents For Electrophotography (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40028914

Family Applications (2)

Family Applications After (1)

Country Status (27)

Families Citing this family (8)

Family Cites Families (12)

• 2008
  • 2008-05-16 FR FR0853187A patent/FR2931073B1/fr active Active
• 2009
  • 2009-05-18 US US12/992,808 patent/US20110071226A1/en not_active Abandoned
  • 2009-05-18 CN CN2009801174703A patent/CN102026632A/zh active Pending
  • 2009-05-18 NZ NZ589971A patent/NZ589971A/xx not_active IP Right Cessation
  • 2009-05-18 CN CN201410366515.3A patent/CN104189005A/zh active Pending
  • 2009-05-18 CA CA2724522A patent/CA2724522A1/fr not_active Abandoned
  • 2009-05-18 SI SI200930080T patent/SI2119435T1/sl unknown
  • 2009-05-18 RU RU2010153201/15A patent/RU2493834C2/ru active
  • 2009-05-18 GE GEAP200912036A patent/GEP20135900B/en unknown
  • 2009-05-18 KR KR1020107028152A patent/KR20110023858A/ko not_active Application Discontinuation
  • 2009-05-18 AU AU2009248047A patent/AU2009248047B2/en not_active Ceased
  • 2009-05-18 AT AT09290370T patent/ATE523192T1/de active
  • 2009-05-18 ES ES09290370T patent/ES2370465T3/es active Active
  • 2009-05-18 WO PCT/EP2009/056021 patent/WO2009138517A1/fr active Application Filing
  • 2009-05-18 PL PL09290370T patent/PL2119435T3/pl unknown
  • 2009-05-18 JP JP2011508948A patent/JP5653911B2/ja not_active Expired - Fee Related
  • 2009-05-18 EP EP09745849A patent/EP2323639A1/fr not_active Withdrawn
  • 2009-05-18 PT PT09290370T patent/PT2119435E/pt unknown
  • 2009-05-18 DK DK09290370.7T patent/DK2119435T3/da active
  • 2009-05-18 UA UAA201015107A patent/UA101035C2/ru unknown
  • 2009-05-18 EP EP09290370A patent/EP2119435B1/fr active Active
  • 2009-05-18 BR BRPI0912506-0A patent/BRPI0912506B1/pt not_active IP Right Cessation
  • 2009-05-18 MX MX2010012352A patent/MX2010012352A/es active IP Right Grant
• 2010
  • 2010-11-15 IL IL209334A patent/IL209334A/en active IP Right Grant
  • 2010-12-15 MA MA33427A patent/MA32396B1/fr unknown
  • 2010-12-15 ZA ZA2010/09033A patent/ZA201009033B/en unknown
• 2011
  • 2011-07-15 HK HK15104391.0A patent/HK1203828A1/xx unknown
  • 2011-12-02 HR HR20110905T patent/HRP20110905T1/hr unknown
  • 2011-12-05 CY CY20111101201T patent/CY1112150T1/el unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events